Research

CENTER FOR INFECTIOUS DISEASE RESEARCH AND POLICY by Lisa Schnerring               March 31, 2015

The US Department of Health and Human Services (HHS) announced today that it has awarded BioCryst Pharmaceuticals a $12 million grant to continue development of BCX4430, a small-molecule drug designed to treat Ebola and other filovirus infections, and to prepare for large-scale manufacturing of the agent.

Studies in nonhuman primates suggest that the drug is effective against Ebola and Marburg viruses and could be useful as a broad-spectrum antiviral, the HHS said in a statement. BCX4430 is currently in phase 1 human trials, and if results show safety, it could be one of the treatments to be tested for efficacy in clinical trials.

BCX4430 is the first small-molecule Ebola treatment that BARDA has supported. Other Ebola products in development that have received BARDA funding include the monoclonal antibody cocktail ZMapp and three vaccines.
Read complete story.
http://www.cidrap.umn.edu/news-perspective/2015/03/biocryst-gets-hhs-contract-ebola-drug-development

The slowdown in the West African Ebola epidemic is welcome news and reason to be hopeful—but it’s also creating a new problem. With fewer new cases occurring, it is becoming more and more difficult to test vaccines and drugs. As a result, conflicts are looming over who can test Ebola drugs and vaccines in Guinea and Sierra Leone.

An Ebola treatment unit in Guinea.Samuel Hanryon/MSF

In Guinea, a large consortium that includes Doctors Without Borders (MSF) and the World Health Organization (WHO) vaccinated the first volunteers at risk of Ebola on Monday in a big trial of a vaccine produced by Merck and NewLink Genetics. But the team feels threatened because researchers at the U.S. National Institutes of Health (NIH) are looking to move another vaccine study from Liberia, where the epidemic has come to a virtual standstill, to Guinea.

NEW YORK - Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, "appear to be safe" part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday.

The two vaccines, each given in a single injection, are being tested for safety and efficacy on more than 600 people in Liberia in a mid-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, a branch of NIH.

The Ebola epidemic that began in West Africa one year ago has killed more than 10,200 people, but a decline in new cases in the most affected countries, Liberia, Guinea and Sierra Leone, has led to hopes that it may be ending.

Based on the encouraging safety results, the study may now advance to the next phase of efficacy testing, in which additional volunteers are injected with the GSK vaccine, the NewLink vaccine, or a dummy shot and assessed to see whether their immune system responds by producing anti-Ebola antibodies.

TIME MAGAZINE  by Alexandra Sifferlin                                             March 25, 2015
An efficacy trial for an Ebola vaccine launched in Guinea on Wednesday.

 A health worker prepares a vaccination on March 10, 2015 at a health center in Conakry during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus.

The vaccine, VSV-EBOV, was developed by the Public Health Agency of Canada and has already shown positive results in smaller safety trials. NewLink Genetics and Merck are collaborating on the vaccine, and the Guinean government and World Health Organization (WHO) are leading the trial, which is taking place in Basse-Guinée, a community where many Ebola cases spread.